Immunotherapy in Turkey

Immunotherapy uses medicines that help your own immune system recognise and attack cancer cells, and in Turkey it is delivered at JCI-accredited oncology centres by multidisciplinary teams, usually as outpatient infusions. For international patients it can be a way to access established checkpoint-inhibitor and other immunotherapy regimens with shorter waits and lower costs than many private routes at home. Whether it is right for you depends entirely on your cancer type, stage and biomarker results — not every cancer or patient responds. Unal Cakar coordinates the medical review, testing and logistics so the decision rests on solid clinical evidence, in partnership with your treating oncologist.

Immunotherapy is a group of cancer treatments that work with your immune system rather than attacking cancer cells directly the way chemotherapy or radiotherapy do. The best-known type, immune checkpoint inhibitors (such as PD-1, PD-L1 and CTLA-4 inhibitors), releases the natural 'brakes' that tumours use to hide from immune cells, allowing your T-cells to recognise and destroy the cancer. Other forms include monoclonal antibodies, therapeutic cancer vaccines, cytokines and, for selected blood cancers, cell-based therapies.

Because it harnesses the immune system, immunotherapy behaves very differently from older treatments: it can produce durable responses in some patients, but it only works when the tumour carries the right biological features. That is why it is never prescribed on diagnosis alone — eligibility is decided by laboratory testing and a specialist team.

Treatment starts with confirming the diagnosis and running biomarker tests on your tumour tissue or blood — for example PD-L1 expression, microsatellite instability (MSI/MMR) status or tumour mutational burden. These results, together with your cancer type, stage and general health, tell the oncology team whether immunotherapy is likely to help and which agent or combination to use, sometimes alongside chemotherapy or targeted therapy.

Most immunotherapy is given as an intravenous infusion in a day-care unit, typically once every two to six weeks in repeated cycles. Each infusion usually takes 30–60 minutes and you go home the same day. Before each cycle you have blood tests and a clinical review, with periodic scans (CT/PET) to measure how the cancer is responding. Treatment continues for as long as it is working and well tolerated.

• Delivered at JCI-accredited oncology centres by multidisciplinary tumour boards.
• Eligibility based on biomarker testing (PD-L1, MSI/MMR, tumour mutational burden).
• Mostly outpatient infusions every 2–6 weeks.
• Independent second-opinion review and records-sharing with your home oncologist included.
• No outcome guarantees — honest, evidence-based candidacy assessment.

1. 01

   Medical review and second opinion

   You share your diagnosis, pathology, scans and prior treatment. An accredited oncology team reviews everything and confirms whether immunotherapy is a realistic option for your specific cancer.

2. 02

   Biomarker and staging tests

   Tumour tissue or blood is tested for markers such as PD-L1, MSI/MMR and tumour mutational burden, and staging scans are updated so the plan is based on current, objective data.

3. 03

   Tumour board treatment plan

   A multidisciplinary tumour board agrees the recommended regimen, schedule and monitoring, and explains the expected benefits, alternatives and risks before you commit.

4. 04

   Infusion cycles and monitoring

   Immunotherapy is given as outpatient infusions on a fixed cycle, with blood tests and reviews before each dose and periodic scans to track response.

5. 05

   Aftercare and continuity

   Your records, scan reports and treatment summary are shared with your oncologist at home so monitoring and any further cycles continue seamlessly.

Immunotherapy suits patients with a confirmed cancer for which it has an established role — such as certain melanomas, lung, kidney, bladder and head-and-neck cancers and Hodgkin lymphoma — whose tumour shows the relevant biomarkers and who are well enough for active treatment. It is generally not suitable, or needs very careful specialist judgement, for people with significant active autoimmune disease, those who have had an organ transplant, or anyone on long-term high-dose immune-suppressing medication, because immunotherapy can worsen these conditions. Pregnancy, very frail health and some uncontrolled infections are also limiting factors. The only way to know is a proper specialist assessment — Unal arranges an independent oncology review so you get an honest answer, including when immunotherapy is not the right path.

• Access to current checkpoint-inhibitor and other evidence-based immunotherapy regimens at JCI-accredited centres.
• Treatment decisions driven by biomarker testing and a multidisciplinary tumour board, not by sales.
• Mostly outpatient infusions, so many patients avoid prolonged hospital stays.
• Faster scheduling than many home waiting lists, with a second-opinion review included.
• Substantially lower cost than private treatment in the UK, US or Gulf for comparable regimens.
• Structured records-sharing so your home oncologist can continue your care.

Immunotherapy is not surgery, so there is no wound to heal — most people return to normal daily activities on the day of each infusion. Some feel tired, achy or feverish for a day or two afterwards, but many continue working and travelling between cycles. Because treatment is given over months, your 'recovery' is really ongoing monitoring rather than a single healing period.

The most important part of aftercare is watching for immune-related side effects, which can appear weeks or even months after a dose and may affect the skin, bowel, lungs, liver or hormone glands. You will be given clear warning signs, contact routes and blood-test schedules, and any reaction is treated promptly — usually with steroids or by pausing treatment. Unal ensures this monitoring plan and your records travel with you so your oncologist at home can act quickly if needed.

Responses to immunotherapy vary widely and cannot be guaranteed. Some patients achieve deep, long-lasting control of their cancer; others have a partial benefit, and a proportion do not respond and need a different approach. When immunotherapy does work, the benefit can be unusually durable, but it often takes several cycles and a follow-up scan (usually after 8–12 weeks) before the team can judge whether the cancer is responding, stable or progressing. Your oncology team will set realistic, individual expectations based on your cancer type, stage and biomarker profile, and will adjust the plan honestly according to what the scans show.

For comparable, evidence-based regimens, immunotherapy delivered at accredited Turkish oncology centres can cost substantially less than equivalent private treatment in the UK, US or Gulf, often with shorter waits and a second-opinion review built in. Drug and regimen costs vary too much to quote a fixed figure, so the clinic provides a written, itemised estimate after reviewing your case — and you pay that clinic directly, never Unal. As an independent facilitator and patient advocate, Unal is sponsored by vetted partner hospitals, coordinates your medical review, testing, logistics and records-sharing, and has no incentive to push treatment you don't need; if immunotherapy isn't right for you, you'll be told.